REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260316:nRSP6653Wa&default-theme=true

RNS Number : 6653W  Haleon PLC  16 March 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

16 March 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 2,749,486 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  12 March 2026
 Number of Shares purchased:                        581,608                -              425,404        242,474
 Highest price paid per Share (p):                  376.6000               -              376.2000       376.2000
 Lowest price paid per Share (p):                   369.3000               -              369.3000       369.3000
 Volume weighted average price paid per Share (p):  373.2269               -              373.3763       373.6357
 Date of purchase:                                  13 March 2026
 Number of Shares purchased:                        701,879                325,243        472,878        -
 Highest price paid per Share (p):                  377.8000               377.8000       377.8000       -
 Lowest price paid per Share (p):                   370.8000               370.8000       370.8000       -
 Volume weighted average price paid per Share (p):  375.3797               375.4187       375.3606       -

 

Following the settlement of the above, the Company's registered share capital
is 8,949,604,162 ordinary shares of £0.01 each, of which 43,651,673 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,905,952,489 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/6653W_1-2026-3-13.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/6653W_1-2026-3-13.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBRGDXRUBDGLX



            Copyright 2019 Regulatory News Service, all rights reserved